BOSTON, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS) announced it will host a conference call today, Wednesday, December 8, 2021, at 4:00 p.m. ET to cover the below:
Original post:
Radius Health to Host Conference Call Today, Wednesday, December 8, 2021
Basel, December 8, 2021 — Novartis today announced new Kisqali® (ribociclib) data demonstrating a consistent overall survival (OS) benefit with Kisqali plus endocrine therapy (ET) across genomic subtypes of hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer (mBC), similarly in the indolent as well as in the aggressive, endocrine therapy (ET)-resistant subtypes6. The findings will be presented as a late-breaking oral presentation at the 2021 San Antonio Breast Cancer Symposium (SABCS).
The rest is here:
New Kisqali® data shows consistent overall survival benefit across genomic and clinical subtypes of interest in HR+/HER2- metastatic breast cancer
WOBURN, Mass., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for Biofrontera Pharma GmbH’s U.S. patent number 17/215,785 (‘785 patent), titled “Illumination device for photodynamic therapy, method for treating a skin disease and method for operating an illumination device,” which protects a number of innovations relating to the RhodoLED XL lamp.
See the rest here:
Biofrontera Inc. Announces Notice of Allowance for U.S. Method-of-Use Patent on PDT-lamp
FLORENCE, Italy and BOSTON, Dec. 08, 2021 (GLOBE NEWSWIRE) -- The Menarini Group (“Menarini”) and Radius Health, Inc. (“Radius”) (NASDAQ: RDUS) (collectively, the “Companies”) provided details on the elacestrant data from the EMERALD trial following the positive results presented today at the San Antonio Breast Cancer Symposium (SABCS). The data was presented as a “Late Breaker” and shared in an oral presentation by Dr. Aditya Bardia, MD.
Go here to see the original:
Positive EMERALD Trial Results for Elacestrant Presented at San Antonio Breast Cancer Symposium 2021
CORAL GABLES, Fla., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced its intention to offer and sell $100 million of shares of its common stock in an underwritten public offering pursuant to its existing shelf registration statement. Relmada also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering on the same terms and conditions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the size or terms of the offering.
Excerpt from:
Relmada Therapeutics Announces Proposed Public Offering of Common Stock
ROCKVILLE, Md., Dec. 08, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or the “Company”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, today announced that stockholders have approved the two proposals voted on at the Company’s Special Meeting of Stockholders held on December 8, 2021.
Read more from the original source:
OpGen Announces Results of Special Meeting of Stockholders
PRINCETON, N.J., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, will host an Investor Day on Wednesday, December 15, 2021 from 3:00 PM to 6:00 PM ET in New York City. Certara’s management team will provide updates on the Company’s strategy, differentiated software and technology-driven services, and financial guidance for 2022. There will also be a demonstration of the Simcyp™ Simulator.
See the rest here:
Certara to Host Investor Day on December 15, 2021
For the Second Year in Row, CB Insights Recognizes BrightInsight for its Leading Global Platform for Biopharma and Medtech Regulated Digital Health Solutions For the Second Year in Row, CB Insights Recognizes BrightInsight for its Leading Global Platform for Biopharma and Medtech Regulated Digital Health Solutions
Original post:
BrightInsight Named to the 2021 CB Insights Digital Health 150 List of Most Innovative Digital Health Startups
New England Journal of Medicine publishes positive Phase 3 Dupixent® (dupilumab) results in children with moderate-to-severe asthma
The rest is here:
New England Journal of Medicine publishes positive Phase 3 Dupixent® (dupilumab) results in children with moderate-to-severe asthma
SAN DIEGO, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for patients with cancer, today announced that management will host a virtual event entitled “B -cell Lymphoma Franchise Update” on Tuesday, December 14, 2021 at 8:00 AM ET.
More:
Fate Therapeutics to Host Virtual Event at the 2021 ASH Annual Meeting